Quick Takeaways
- Ikarian Capital, LLC filed SCHEDULE 13G for Channel Therapeutics Corp Common Stock, par value $0.0001 per share (CHRO).
- Disclosed ownership: 7.3%.
- Date of event: 31 Dec 2024.
Ikarian Capital, LLC - 31 Dec 2024 SCHEDULE 13G Report for Channel Therapeutics Corp Common Stock, par value $0.0001 per share (CHRO)
- Filing Manager
- Ikarian Capital, LLC
- Reporting Manager
- Ikarian Capital, LLC
- Symbol
- CHRO
- Shares outstanding
- 6,039,027 shares
- Disclosed Ownership
- 440,849 shares
- Ownership
- 7.3%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Feb 2025, 13:09:03 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Ikarian Capital, LLC disclosed 7.3% ownership in Channel Therapeutics Corp Common Stock, par value $0.0001 per share (CHRO) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 13:09.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Ikarian Capital, LLC | 7.3% | 440,849 | 0 | 440,849 | /s/ Neil Shahrestani | Neil Shahrestani, Sole Manager | |
| Neil Shahrestani | 7.3% | 440,849 | 0 | 440,849 | /s/ Neil Shahrestani | Neil Shahrestani |